Neusignal Therapeutics

Neusignal Therapeutics, founded in April 2022, is a biotechnology firm that originated as a spin-off from Tohoku University in Japan. The company was established based on the research of founder Moriguchi Shigeki, an associate professor at Tohoku University, who now serves as a special advisor. The current CEO is Yoshifumi Yoshida, who brought experience from a large corporation's spin-out venture and a background in life sciences and healthcare. His motivation stems from a personal connection to new medicine and a desire to tackle a new challenge later in his career.

The company's primary focus is on developing therapeutics for central nervous system (CNS) diseases, with a specific emphasis on Alzheimer's disease and other forms of dementia and psychiatric disorders. Neusignal is tackling the high unmet medical need for effective Alzheimer's treatments in a rapidly aging global society. The business operates in the drug discovery and biotechnology sector, aiming to commercialize its research by developing and bringing new drugs to market. Its business model revolves around the research and development of pharmaceutical products, with revenue generation anticipated from the successful commercialization, licensing, or partnership of its drug candidates.

Neusignal's leading product candidate is NTX-083, a small molecule oral drug intended for the treatment of Alzheimer's disease. This drug is designed to address various pathological conditions of the disease, potentially repairing nerve cells through a novel mechanism of action. A key feature of NTX-083 is its format as an oral medication, which allows for less expensive, at-home treatment compared to other therapies. This approach aims to not only slow disease progression but also manage peripheral symptoms like depression and wandering, thereby improving patient quality of life and reducing the burden on caregivers. The company has successfully raised significant capital to advance its pipeline, including a Series A round in early 2025 totaling approximately 2.2 billion yen, which was comprised of 1.15 billion yen from investors and a 1.1 billion yen subsidy from the Japan Agency for Medical Research and Development (AMED). These funds are designated for an upcoming investigator-initiated Phase 1 clinical trial and preparations for a company-led Phase 1b trial in the U.S.

Keywords: Neusignal Therapeutics, Alzheimer's disease treatment, CNS disorders, drug discovery, biotechnology, Tohoku University spin-off, oral small molecule drugs, NTX-083, dementia therapy, neurodegenerative disease, clinical trials, pharmaceutical development, Moriguchi Shigeki, Yoshifumi Yoshida, at-home care, neurological therapeutics, psychiatric disorders, venture capital, AMED, central nervous system